ME01616B - Kinolinski derivati kao antibakterijski agensi - Google Patents

Kinolinski derivati kao antibakterijski agensi

Info

Publication number
ME01616B
ME01616B MEP-2013-65A MEP6513A ME01616B ME 01616 B ME01616 B ME 01616B ME P6513 A MEP6513 A ME P6513A ME 01616 B ME01616 B ME 01616B
Authority
ME
Montenegro
Prior art keywords
alkyl
halo
lil
amino
alkyloxy
Prior art date
Application number
MEP-2013-65A
Other languages
English (en)
Inventor
J E G Guillemont
E T J Pasquier
David Francis Alain Lançois
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Leo Jacobus Jozef Backx
Lieven Meerpoel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35744723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01616(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ME01616B publication Critical patent/ME01616B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na upotrebu jedinjenja za proizvodnju leka za tretman  ba kterijske  infe kcije koja je uzrokovana sa  Staphylococci ,  Enterococci   ili   Streptococci , pri čemu je spomenuto jedinjenje neko jedinjenje sa formulom  (I)         (I) neke njegov e  farmaceutski prihvatljiv e  kisel e  ili bazn e  adicion e  so li ,  kvaternarn og  amin a ,  stereohemijski izomern e forme , tautomer n e  form e  ili nek og  njegov og   N -o ksid a , gde : R 1          je   vodonik , halo, halo alkil ,  cijano ,  hidroksi , Ar, Het,  alkil ,  alkiloksi ,  alkiltio ,  alkiloksialkil ,  alkiltioalkil, Ar-alkil ili di(Ar)alkil ; p          je   celi broj jednak  1, 2  ili  3; s          je   celi broj jednak nuli , 1, 2, 3  ili  4; R 2          je   vodonik ; halo;  alkil ;  hidroksi ; mer k apto;  alkiloksi   koji je ponekad supstituisan sa  amino  ili  mono  ili  di( alkil )amino  ili je  radi k al  sa  formul om   gde  Z  je  CH 2 , CH-R 8 , O, S, N-R 8 ,  a   t  je celi broj koji je jednak  1  ili  2 ,  a  tačkasta linija  predstavlja  neku moguću vezu ;  alkiloksialkiloksi ;  alkiltio ; mono  ili  di( alkil )amino  gde   alkil  m ože ponekad da bude supstituisan sa jednim ili dva  su pstituenta koja su nezavisno izabrana iz  alkiloksi   ili  Ar  ili  Het  ili   morfolinila   ili  2- oksopiro lidi nila ; Ar; Het  ili neki  radi k al  sa  formul om   gde  Z  je  CH 2 , CH-R 8 , O, S, N-R 8 ; t  je celi broj jednak  1  ili  2; a  tačkasta linija predstavlja moguću vezu ; R 3          je   alkil , Ar, Ar- alkil , Het  ili  Het- alkil ; q          je celi broj jednak nuli , 1, 2, 3  ili  4; R 4   i  R 5            svaki nezavisno su vodonik ,  alkil   ili   benzil ;  ili R 4   i  R 5   zajedno   i uključujući  N  na kojeg su spojeni mogu da formiraju  radi k al  koji je izabran iz  grup e koja obuhvata  piro lidi nil , 2- pirolinil , 3- pirolinil ,  piro lil , imidazolidi nil ,  pira zolidi nil , 2-imidazo linil , 2- pira zo linil , imidazo lil ,  pira zo lil , triazo lil , piperidi nil ,  piri di nil , piperazi nil ,  piri dazi nil ,  piri midi nil ,  pira zi nil , triazi nil ,  morfolinil   i   tio morfolinil ,  a svaki od pomenutih prstena je ponekad supstituisan sa  alkil om , halo, halo alkil om ,  hidroksi ,  alkiloksi , amino, mono-  ili  di - alkil amino,  alkiltio ,  alkiloksialkil om ,  alkiltioalkil om i   piri midi nil om ; R 6          je   vodonik , halo, halo alkil ,  hidroksi , Ar,  alkil ,  alkiloksi ,  alkiltio ,  alkiloksialkil ,  alkiltioalkil , Ar- alkil   ili  di(Ar) alkil ;  ili dva susedna  R 6  radi kala mogu  zajedno sa fenilnim prstenom na kojeg su spojeni  da  formiraju  na f t i l; r          je   celi broj jednak  1, 2, 3, 4  ili  5;  a R 7          je   vodonik ,  alkil , Ar  ili  Het; R 8          je   vodonik ,  alkil ,  hidroksi l, amino k arbo nil , mono-  ili  di( alkil )amino k arbo nil , Ar, Het,  alkil  su pstituisan sa jednim ili dva  Het,  alkil  su pstituisan sa jednim ili dva  Ar, Het-C(=O)-  ili  Ar-C(=O)-; alkil            je   ravan ili razgranat zasićeni  ugljovodonički   radi k al  koji ima od  1  d o 6  atoma ugljenika ;  ili je  c iklički zasićeni  ugljovodonički   radi k al  koji ima od  3  d o 6  atoma ugljenika ;  ili je ciklički zasićeni  ugljovodonički   radi k al  koji ima od  3  d o 6  atoma ugljenika koji su spojeni na ravni ili razgranati  zasićeni   ugljovodonički   radi k al  koji ima od  1  d o 6  atoma ugljenika ;  gde svaki atom ugljenika može ponekad da bude supstituisan sa  hidroksi ,  alkiloksi   ili   okso ; Ar           je  homoc ikal koji je izabran iz  grup e koja obuhvata fenil ,  naftil , ace naftil , tetra hidro naftil ,  a svaki je ponekad supstituisan sa  1, 2  ili  3 su pstituenta ,  a svaki supstituent je nezavisno izabran iz  grup e koja obuhvata  hidroksi , halo,  cijano , nitro, amino, mono-  ili  di alkil amino,  alkil , halo alkil ,  alkiloksi , halo alkiloksi ,  k arb oksi l,  alkiloksi k arbo nil ,  alkil k arbo nil , amino k arbo nil ,  morfolinil   i  mono-  ili  di alkil amino k arbo nil ; Het          je  monoc iklički  heteroc ikal koji je izabran iz  grup e koja obuhvata   N- f en oksi piperidi nil , piperidi nil ,  piro lil ,  pira zo lil , imidazo lil , fura nil ,  tie nil ,  oksa zo lil ,  izoksa zo lil ,  tia zo lil ,  izotia zo lil , triazo lil ,  piri di nil ,  piri midi nil ,  pira zi nil   i   piri dazi nil ;  ili je  bic iklički  heteroc ikal koji je izabran iz  grup e   kino linil a ,  izokino linil a , 1,2,3,4-tetra hidro izokino linil a ,  kinoksa linil a , indo lil a , indazo lil a , benzimidazo lil a , benz oksa zo lil a , benz izoksa zo lil a , benzo tia zo lil a , benz izotia zo lil a , benzofura nil a , benzo tie nil a , 2,3-di hidro benzo[1,4]di oksi nil a   ili  benzo[1,3]di okso lil a ;  a svaki  monoc iklički i  bic iklički  heteroc ikal može ponekad  da  bude supstituisan na atomu ugljenika sa  1, 2  ili  3 su pstituenta ,  a svaki  su pstituent je nezavisno izabran iz  grup e  halo,  hidroksi ,  alkil a   ili   alkiloksi ; halo          je  su pstituent koji je izabran iz  grup e  fluoro,  hloro , bromo  i   jodo   i halo alkil          je   ravan ili razgranat  zasićen   ugljovodonički  r adi k al  koji ima od  1  d o 6  atoma ugljenika ili je  c iklički  zasićeni   ugljovodonički  radikal koji ima od  3  d o 6  atoma ugljenika ili je  c iklički  zasićeni   ugljovodonički   radi k al  koji ima od  3  d o 6  atoma ugljenika koji je spojen na ravan ili razgranat  ugljovodonički  r adi k al  koji ima od  1  d o 6  atoma ugljenika ;  gde je jedan ili više atoma ugljenika supstituisano sa jednim ili više halo atoma; p od   uslovom da kada  radi k al  se nalazi na poziciji  3  u kinolinskom ostatku ; R 7   se nalazi na poziciji  4  u  kinolin skom ostatku, a  R 2   se nalazi na poziciji  2  u  kinolin skom ostatku i predstavlja vodonik ,  hidroksi , mer k apto,  alkiloksi ,  alkiloksialkiloksi ,  alkiltio , mono  ili  di( alkil )amino  ili  radi k al  sa  formul om   gde  Y  je  CH 2 , O, S, NH  ili   N- alkil ; a tada  s  je  1, 2, 3  ili  4 .
MEP-2013-65A 2005-08-03 2006-07-31 Kinolinski derivati kao antibakterijski agensi ME01616B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107164 2005-08-03
EP06778083.3A EP1912648B1 (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterial agents
PCT/EP2006/064858 WO2007014941A2 (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterial agents

Publications (1)

Publication Number Publication Date
ME01616B true ME01616B (me) 2014-09-20

Family

ID=35744723

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2013-65A ME01616B (me) 2005-08-03 2006-07-31 Kinolinski derivati kao antibakterijski agensi

Country Status (31)

Country Link
US (1) US8802671B2 (me)
EP (1) EP1912648B1 (me)
JP (1) JP5302680B2 (me)
KR (1) KR101413997B1 (me)
CN (2) CN101277696B8 (me)
AP (1) AP2654A (me)
AR (1) AR054890A1 (me)
AU (1) AU2006274880B2 (me)
BR (1) BRPI0614493B8 (me)
CA (1) CA2615903C (me)
CY (1) CY1114318T1 (me)
DK (1) DK1912648T3 (me)
EA (1) EA014833B1 (me)
ES (1) ES2414956T3 (me)
HK (1) HK1124234A1 (me)
HR (1) HRP20130540T1 (me)
IL (1) IL189142A0 (me)
JO (1) JO2855B1 (me)
ME (1) ME01616B (me)
MX (1) MX2008001603A (me)
MY (1) MY159560A (me)
NO (1) NO341242B1 (me)
NZ (1) NZ565947A (me)
PL (1) PL1912648T3 (me)
PT (1) PT1912648E (me)
RS (1) RS52808B (me)
SI (1) SI1912648T1 (me)
TW (1) TWI422374B (me)
UA (1) UA95915C2 (me)
WO (1) WO2007014941A2 (me)
ZA (1) ZA200801110B (me)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004186452A (ja) 2002-12-04 2004-07-02 Renesas Technology Corp 不揮発性半導体記憶装置およびその製造方法
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
WO2013160431A1 (en) 2012-04-27 2013-10-31 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
EP2841425B1 (en) 2012-04-27 2016-03-23 Janssen Pharmaceutica, N.V. Antibacterial quinoline derivatives
EP2909192B1 (en) 2012-10-16 2017-05-17 Janssen Pharmaceutica NV Methylene linked quinolinyl modulators of ror-gamma-t
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
JP6250686B2 (ja) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ.ベー. Rorγtのヘテロアリール結合させたキノリニルモジュレータ
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
CN109111396B (zh) * 2018-08-28 2021-09-03 广东工业大学 一种喹啉芳香乙烯衍生物及其制备方法和应用
CN109111397B (zh) * 2018-08-28 2021-12-10 广东工业大学 一种喹啉芳香乙烯类衍生物及其制备方法和应用
CN112110907B (zh) * 2020-10-09 2021-12-21 中央民族大学 一种含1,4-二氧六环二聚双噻吩结构的化合物及其制备方法和应用
CN112079825B (zh) * 2020-10-09 2021-12-21 中央民族大学 含1,3-二氧戊环二聚双噻吩结构的化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB807750A (en) * 1956-06-15 1959-01-21 Rhone Poulenc Sa Improvements in or relating to piperazine derivatives
GB9317491D0 (en) * 1993-08-23 1993-10-06 Fujisawa Pharmaceutical Co New compound and a process for preparation thereof
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
CN1325475C (zh) * 2002-07-25 2007-07-11 詹森药业有限公司 喹啉衍生物及其作为分枝杆菌抑制剂的应用
PL360102A3 (en) 2003-05-13 2004-11-15 "ENERGOMAR-NORD" Sp.z o.o. Method for manufacturing highly reactive calcium sorbing agents and facility designed for manufacturing highly reactive calcium sorbing agents
WO2005070430A1 (en) 2004-01-23 2005-08-04 Janssen Pharmaceutica N.V. Quinoline derivatives and use thereof as mycobacterial inhibitors
BRPI0507076B8 (pt) 2004-01-23 2021-05-25 Janssen Pharmaceutica Nv quinolinas substituídas, seu processo de preparação, composição farmacêutica que as compreende e seu uso como inibidores micobacterianos
EP1713776B1 (en) * 2004-01-29 2008-05-14 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
US20070018948A1 (en) 2005-07-22 2007-01-25 Elaine Chen Apparatus for stabilizing an electronic device during data input and device control

Also Published As

Publication number Publication date
BRPI0614493B1 (pt) 2019-11-12
CN101277696B8 (zh) 2016-07-06
UA95915C2 (ru) 2011-09-26
CY1114318T1 (el) 2016-08-31
TW200744595A (en) 2007-12-16
CN101277696B (zh) 2015-09-02
AU2006274880B2 (en) 2012-12-13
CN101277696A (zh) 2008-10-01
KR101413997B1 (ko) 2014-07-01
EA200800508A1 (ru) 2008-06-30
JO2855B1 (en) 2015-03-15
BRPI0614493B8 (pt) 2021-05-25
AR054890A1 (es) 2007-07-25
ZA200801110B (en) 2011-10-26
DK1912648T3 (da) 2013-06-24
IL189142A0 (en) 2008-08-07
ES2414956T3 (es) 2013-07-23
MX2008001603A (es) 2008-02-19
HK1124234A1 (zh) 2009-07-10
NZ565947A (en) 2011-05-27
AU2006274880A1 (en) 2007-02-08
KR20080035666A (ko) 2008-04-23
AP2654A (en) 2013-04-25
MY159560A (en) 2017-01-13
SI1912648T1 (sl) 2013-07-31
JP2009503025A (ja) 2009-01-29
NO20081026L (no) 2008-02-27
PL1912648T3 (pl) 2013-08-30
US20080207687A1 (en) 2008-08-28
WO2007014941A2 (en) 2007-02-08
CA2615903A1 (en) 2007-02-08
EP1912648B1 (en) 2013-04-10
WO2007014941A3 (en) 2007-03-29
EP1912648A2 (en) 2008-04-23
TWI422374B (zh) 2014-01-11
WO2007014941A8 (en) 2007-05-31
PT1912648E (pt) 2013-06-27
US8802671B2 (en) 2014-08-12
RS52808B (en) 2013-10-31
EA014833B1 (ru) 2011-02-28
NO341242B1 (no) 2017-09-25
BRPI0614493A2 (pt) 2011-03-29
JP5302680B2 (ja) 2013-10-02
CA2615903C (en) 2016-08-30
HRP20130540T1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
ME01616B (me) Kinolinski derivati kao antibakterijski agensi
Gao et al. Recent developments of quinolone-based derivatives and their activities against Escherichia coli
CA2932169C (en) Substituted 1h-pyrrolo[2,3-b]pyridine and 1h-pyrazolo[3,4-b]pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors
CA2371645C (en) Naphtalene or heterocyclically substituted benzimidazoles as parp inhibitors
AU2009267827B2 (en) Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
ATE319446T1 (de) Neue prolinverbindungen als mikrobizide mittel
WO2007095124A2 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
NO20080955L (no) Kinolinderivater som antibakterielle midler
JP2016517412A (ja) Fasnを阻害するための新規化合物および組成物
JP2020510092A5 (me)
Carta et al. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase
EP3371151A1 (en) Compounds for treatment of cancer and epigenetics
BR112015004967A2 (pt) amino-quinolinas como inibidores de quinase
Abdel‐Megid et al. Synthesis of Some New Nitrogen Bridge‐head Triazolopyridines, Pyridotriazines, and Pyridotriazepines Incorporating 6‐Methylchromone Moiety
JP2017537933A (ja) 新規な抗菌性化合物
JP2005511760A (ja) 新規な化合物
Gao et al. Synthesis and antibacterial activity of novel [1, 2, 4] triazolo [3, 4-h][1, 8] naphthyridine-7-carboxylic acid derivatives
NO20081068L (no) Kinolinderivater som antibakterielle midler
WO2008053863A1 (fr) Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one
AU2014261512A1 (en) Pd-catalyzed coupling of pyrazole amides
US6699861B1 (en) Anti-quinazoline compounds
AU2009333653B2 (en) C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
JP2021511364A (ja) 抗菌剤として有用な複素環式化合物
AU2016333293B2 (en) Salt type and crystal type of 4H-pyrazolo (1, 5-alpha) benzimidazole compound and preparation method and intermediate thereof
GB2031404A (en) Pyridazinone compounds